MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.carrev.2024.02.002

Медицинская библиотека · Cardiovascular revascularization medicine : including molecular interventions · 2024

Management strategies and prognosis of patients ineligible for transcatheter mitral valve replacement.

Hasan Syeda A, Morsi Moustafa, Frakes Belinda S, Bryson Marien E, Schmidt Christian W, Seshiah Puvi, Choo Joseph, Smith J Michael, Answini Geoffrey A, Stewart-Dehner Terri L, Yasar Senan J, Jollis James G, Berlacher Mark D, Ratajczak Teresa M, Chung Eugene S, Kereiakes Dean J, Garcia Santiago

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Transcatheter mitral valve replacement (TMVR) faces anatomical challenges, currently limiting widespread adoption.

OBJECTIVES

To describe the natural history and prognosis of patients ineligible for various TMVR devices.

METHODS

During a 4-year period (2019-2023) 3 TMVR devices (SAPIEN M3, Intrepid and Alta Valve) became available at a single institution (The Christ Hospital, Cincinnati, OH) in the setting of pivotal clinical trials or early feasibility study. Consenting patients who were deemed ineligible ≥1 of these trials were prospectively studied to capture anatomical reasons for ineligibility, cross-over to alternative mitral valve therapies (surgery or high-risk mitral transcatheter edge to edge repair [M-TEER]), and clinical events.

RESULTS

A total of 61 patients (out of 71 consenting patients or 85.9 %) were deemed ineligible for TMVR during the study period. The mean age was 79.2 ± 8.8 years, 65.6 % were female, with elevated surgical risk (median STS 4.3, IQR: 2.7-7.3). The 2 most common anatomical reasons for ineligibility were increased risk of left ventricular outflow tract obstruction (LVOTO) (n = 24, 39.3 %) and annular size (n = 29, 47.5 %). During follow-up (median 277 [162-555] days) there were 7 deaths (11.5 %) and 12 (19.7 %) hospitalizations for heart failure. Management strategies included high-risk M-TEER in 11 patients (1 death [9.0 %], 0 HF hospitalizations [0 %]), surgery in 9 patients (0 deaths, 1 HF hospitalizations [11.1 %]), and medical management in 41 patients (6 deaths [14.6 %], 11 HF hospitalizations [26.8 %]) (p = 0.715 for mortality and p = 0.093 for HF hospitalizations). Residual MR ≥ moderate was 0 %, 50 %, and 100 % for surgery, M-TEER and medical treatment, respectively (p < 0.001).

CONCLUSIONS

One third of patients deemed ineligible for TMVR are candidates for high-risk M-TEER or surgery with acceptable morbidity and mortality. Our results have practical implications for patient management.

Для цитирования: Hasan Syeda A, Morsi Moustafa, Frakes Belinda S, Bryson Marien E, Schmidt Christian W, Seshiah Puvi, Choo Joseph, Smith J Michael, Answini Geoffrey A, Stewart-Dehner Terri L, Yasar Senan J, Jollis James G, Berlacher Mark D, Ratajczak Teresa M, Chung Eugene S, Kereiakes Dean J, Garcia Santiago. Management strategies and prognosis of patients ineligible for transcatheter mitral valve replacement.. Cardiovascular revascularization medicine : including molecular interventions. 2024. DOI: 10.1016/j.carrev.2024.02.002.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.